Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
| ▸ | LCAT | P04180 | 2/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735671 | 0.81 | CHRNB2 (0.46) | OPRM1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL736441 | 0.81 | SIGMAR1 (0.42) | OPRM1OPRL1KCNH2SIGMAR1LCAT | |
| SCHEMBL737073 | 0.81 | SIGMAR1 (0.46) | OPRM1OPRL1KCNJ1KCNH2SIGMAR1 | |
| SCHEMBL736596 | 0.78 | SIGMAR1 (0.46) | OPRM1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL737026 | 0.77 | SIGMAR1 (0.47) | OPRM1SIGMAR1FASN | |
| SCHEMBL737485 | 0.74 | SIGMAR1 (0.40) | OPRM1SIGMAR1 | |
| SCHEMBL737442 | 0.74 | SIGMAR1 (0.62) | OPRM1KCNH2SIGMAR1 | |
| SCHEMBL736367 | 0.72 | OPRM1 (0.40) | OPRM1OPRL1KCNJ1SIGMAR1 | |
| SCHEMBL736328 | 0.72 | SIGMAR1 (0.40) | OPRM1OPRL1CHRNB2CHRNA4KCNH2 | |
| SCHEMBL735954 | 0.72 | SIGMAR1 (0.40) | OPRM1OPRL1CHRNB2CHRNA4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | OPRM1 15/4885OPRL1 33/4885CHRNB2 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.